Pulmonx (NASDAQ:LUNG - Get Free Report) will be announcing its earnings results after the market closes on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Pulmonx has set its FY 2024 guidance at EPS.Individual interested in registering for the company's earnings conference call can do so using this link.
Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its earnings results on Wednesday, July 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.02. The company had revenue of $20.78 million for the quarter, compared to analysts' expectations of $20.23 million. Pulmonx had a negative net margin of 75.56% and a negative return on equity of 50.79%. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Pulmonx Price Performance
Shares of LUNG remained flat at $6.13 during mid-day trading on Wednesday. 208,102 shares of the company were exchanged, compared to its average volume of 404,585. The company has a debt-to-equity ratio of 0.37, a quick ratio of 7.92 and a current ratio of 8.97. The company has a 50-day moving average of $7.31 and a two-hundred day moving average of $7.34. Pulmonx has a 12-month low of $5.46 and a 12-month high of $14.84. The stock has a market capitalization of $237.94 million, a price-to-earnings ratio of -3.98 and a beta of 0.64.
Analysts Set New Price Targets
LUNG has been the subject of several research reports. Canaccord Genuity Group upped their price objective on Pulmonx from $15.00 to $16.00 and gave the stock a "buy" rating in a research report on Thursday, August 1st. Wells Fargo & Company dropped their target price on shares of Pulmonx from $14.00 to $10.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 1st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $14.83.
View Our Latest Report on LUNG
Insider Buying and Selling at Pulmonx
In other Pulmonx news, Director Glendon E. French III sold 20,000 shares of the firm's stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $6.52, for a total transaction of $130,400.00. Following the completion of the transaction, the director now owns 1,091,974 shares of the company's stock, valued at approximately $7,119,670.48. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Steven S. Williamson acquired 14,245 shares of the business's stock in a transaction dated Tuesday, August 20th. The shares were bought at an average cost of $6.84 per share, for a total transaction of $97,435.80. Following the acquisition, the chief executive officer now directly owns 219,531 shares in the company, valued at $1,501,592.04. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Glendon E. French III sold 20,000 shares of the firm's stock in a transaction that occurred on Thursday, October 17th. The shares were sold at an average price of $6.52, for a total transaction of $130,400.00. Following the completion of the transaction, the director now owns 1,091,974 shares in the company, valued at $7,119,670.48. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,351 shares of company stock valued at $361,494. Insiders own 5.70% of the company's stock.
About Pulmonx
(
Get Free Report)
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Featured Stories
Before you consider Pulmonx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulmonx wasn't on the list.
While Pulmonx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
